Detalhe da pesquisa
1.
Efficacy and safety of tepotinib in Asian patients with advanced NSCLC with MET exon 14 skipping enrolled in VISION.
Br J Cancer
; 130(10): 1679-1686, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38575731
2.
A randomized Phase 2 study to compare erlotinib with or without bevacizumab in previously untreated patients with advanced non-small cell lung cancer with EGFR mutation.
Cancer
; 129(3): 405-414, 2023 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36451343
3.
Single targeting of MET in EGFR-mutated and MET-amplified non-small cell lung cancer.
Br J Cancer
; 128(12): 2186-2196, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37059804
4.
Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer.
N Engl J Med
; 383(10): 944-957, 2020 09 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-32877583
5.
Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations.
N Engl J Med
; 383(10): 931-943, 2020 09 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-32469185
6.
Olmutinib in T790M-positive non-small cell lung cancer after failure of first-line epidermal growth factor receptor-tyrosine kinase inhibitor therapy: A global, phase 2 study.
Cancer
; 127(9): 1407-1416, 2021 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33434335
7.
One-Step Polymerase Chain Reaction-Free Nanowire-Based Plasma Cell-Free DNA Assay to Detect EML4-ALK Fusion and to Monitor Resistance in Lung Cancer.
Oncologist
; 26(10): e1683-e1692, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34272914
8.
Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer.
N Engl J Med
; 379(21): 2027-2039, 2018 11 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-30280657
9.
ELF3 Is a Target That Promotes Therapeutic Efficiency in EGFR Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer Cells via Inhibiting PKCί.
Int J Mol Sci
; 22(22)2021 Nov 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-34830169
10.
Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study.
Lancet Oncol
; 21(3): 373-386, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-32027846
11.
Epidermal growth factor receptor mutation analysis in tissue and plasma from the AURA3 trial: Osimertinib versus platinum-pemetrexed for T790M mutation-positive advanced non-small cell lung cancer.
Cancer
; 126(2): 373-380, 2020 01 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31769875
12.
Psychometric properties and factor structure of the Korean version of the screen for child anxiety related emotional disorders (SCARED).
BMC Psychiatry
; 20(1): 89, 2020 02 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-32111188
13.
Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-2 study.
Lancet Oncol
; 20(12): 1681-1690, 2019 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31587882
14.
Direct isolation and characterization of circulating exosomes from biological samples using magnetic nanowires.
J Nanobiotechnology
; 17(1): 1, 2019 Jan 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-30612562
15.
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.
Lancet
; 387(10027): 1540-1550, 2016 Apr 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-26712084
16.
Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study.
Lancet Oncol
; 17(12): 1643-1652, 2016 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-27751847
17.
PNA clamping-assisted fluorescence melting curve analysis for detecting EGFR and KRAS mutations in the circulating tumor DNA of patients with advanced non-small cell lung cancer.
BMC Cancer
; 16: 627, 2016 08 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-27519791
18.
Attitudes toward disclosure of medication side effects: a nationwide survey of Korean patients, caregivers, and oncologists.
Psychooncology
; 24(11): 1398-406, 2015 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-25970704
19.
Clinical outcome according to the level of preexisting epidermal growth factor receptor T790M mutation in patients with lung cancer harboring sensitive epidermal growth factor receptor mutations.
Cancer
; 120(14): 2090-8, 2014 Jul 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-24737599
20.
Ventriculolumbar perfusion chemotherapy with methotrexate for treating leptomeningeal carcinomatosis: a Phase II Study.
Oncologist
; 19(10): 1044-5, 2014 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-25209375